moexipril

Trade name: univasc

Small moleculeapproved

Approved

Apr 19, 1995

Moexiprilat is the pharmacologically active metabolite of Moexipril. Formation of Moexiprilat is caused by hydrolysis of a Moexipril’s ethyl ester group. Moexiprilat competitively inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the actions of the potent vasoconstrictor angiotensin II and leads to vasodilatation. This agent also prevents angiotensin II-induced aldosterone secretion by the adrenal cortex, thereby promoting diuresis and natriuresis. Moexiprilat showed an extended duration of action owing to a long terminal pharmacokinetic half-life and produced a persistent ACE inhibition. — NCATS

Clinical trial activity

5 trials · 6 clinical orgs · 8 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Jun 1, 2003 (NCT00588302)

Timeline

1990s

Apr 19, 1995
Earliest FDA Approval
Apr 19, 1995
UCB — NDA Secondary Org

2000s

Jan 1, 2003
Teva — Earliest Phase 1 Sponsor(trial)
Jan 1, 2003
Earliest Phase 2 Sponsor(trial)
May 8, 2003
Teva — Marketing Organization
Nov 30, 2006
Chartwell Pharmaceuticals — Marketing Organization
Jun 2, 2008
Apotex — Marketing Organization

2010s

Mar 30, 2010
Glenmark Pharmaceuticals — Marketing Organization
Mar 7, 2014
Heritage Pharma — Marketing Organization
Mar 7, 2014
Emcure — Marketing Organization

Indications

Approved for

Hypertension

Studied for

Mechanism of action

Angiotensin-converting enzymeINHIBITOR
ACE inhibitor
- Angiotensin-converting enzyme (ACE) ↗

Combination products

uniretic
with hydrochlorothiazide

Approval history

approvedApr 19, 1995

Chemistry & pharmacology

Loading structure…

SMILES

CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1Cc2cc(OC)c(OC)cc2C[C@H]1C(=O)O

Mol. weight: 498.58 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Delivery: Oral
Availability: Prescription Only

Oral

Yes

Parenteral

Topical

Black box warningProdrug

Sources

Also known as

2-((1-ethoxycarbony)-3-phenylpropylamino-1-oxopropyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid
ci-925
ci-925
fempress
moclobenid
moex
moexipril
moexipril
moexipril
moexipril
moexipril
moexipril
moexipril
moexipril
moexipril
moexipril
moexipril hcl
moexipril hcl
moexipril hcl
moexipril hydrochloride
moexipril hydrochloride
moexipril hydrochloride
moexipril hydrochloride
moexipril hydrochloride
moexiprilum
moexiprilum
moexpiril
perdix
perdix
perdix
rs 10085
rs-10085
rs-10085-197
rs-10085-197
spm-925
spm-925
uniretic
uniretic
uniretic
univasc
univasc
univasc
univasc
univasc

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT00992862	Phase 1	Oct 7, 2009	Novum Pharmaceutical Research Services, Paddock Laboratories
NCT00990301	Phase 1	Oct 4, 2009	Novum Pharmaceutical Research Services, Paddock Laboratories
NCT00834067	Phase 1	Oct 1, 2003	Gateway Medical Research, Teva
NCT00835042	Phase 1	Oct 1, 2003	Gateway Medical Research, Teva
NCT00588302	Phase 2	Jun 1, 2003	Hoosier Cancer Research Network, Mayo Clinic

Showing 5 of 5 trials

Page 1 / 1

Organizations

Research & Development (6)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Gateway Medical Research	For profit	2	0	1	2003
Novum Pharmaceutical Research Services	For profit	2	0	1	2009
Paddock Laboratories	For profit	2	2	1	2009
Teva	For profit	2	2	1	2003
Hoosier Cancer Research Network	Academic/Hospital	1	0	1	2003
Mayo Clinic	Academic/Hospital	1	1	1	2003

6 organizations

Page 1 / 1

Marketing (12)

Organization	Org type	Relationship	Date
Apotex	For profit	MKTG	Jun 2, 2008
Besselaar	For profit	NDA	—
Chartwell Pharmaceuticals	For profit	MKTG	Nov 30, 2006
Emcure	For profit	MKTG	Mar 7, 2014
Glenmark Pharmaceuticals	For profit	MKTG	Mar 30, 2010
Glenmark Pharmaceuticals	For profit	SYN	Mar 17, 2010
Glenmark Pharmaceuticals	For profit	SYN	Mar 30, 2010
Heritage Pharma	For profit	MKTG	Mar 7, 2014
Heritage Pharma	For profit	SYN	Mar 7, 2014
Heritage Pharma	For profit	SYN	Mar 7, 2014
Teva	For profit	MKTG	May 8, 2003
UCB	For profit	NDA2	Apr 19, 1995